Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | EVP, Strategy & Corporate Dev | January 28, 2025 | January 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date January 28, 2025 · Filed January 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,044 |
Last balance in matching sequence
After 2025-01-29 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-01-28 · Grant · Acquired 3,048 · Balance 43,227 F1: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025. F2: Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025, and 104 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on August 30, 2024. Row 2 · 2025-01-29 · Sale · Disposed 1,183 · Balance 42,044 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025, and 104 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on August 30, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025.
F2: Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025, and 104 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on August 30, 2024.
F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 29, 2025 Filed Jan 30, 2025 23:44 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,183 | $86.91 | $102,819.74 |
DisclosureSEC source: 0001093557-25-000018 · wk-form4_1738280660.xml · nonDerivative · entry 2 Dolan Matthew Vincent · CIK 0001914994 · EVP, Strategy & Corporate Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,044 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025, and 104 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on August 30, 2024. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 23:44 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 3,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-25-000018 · wk-form4_1738280660.xml · nonDerivative · entry 1 Dolan Matthew Vincent · CIK 0001914994 · EVP, Strategy & Corporate Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,227 F1 · kind: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025. F1 · shares: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025. F2 · balance_after: Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025, and 104 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on August 30, 2024. Read SEC document |
| May 15, 2024 Filed May 16, 2024 20:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,423 | $126.58 | $306,703.34 |
DisclosureSEC source: 0001093557-24-000083 · edgardoc.xml · nonDerivative · entry 1 Dolan Matthew Vincent · CIK 0001914994 · EVP Strategy and Corporate Dev 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,075 F1 · shares: On December 15, 2023, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025 and 121 additional shares purchased pursuant to the DexCom, Inc. 2015 Employee Stock Purchase Plan. Read SEC document |
| April 15, 2024 Filed Apr 16, 2024 20:16 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,990 | $137.81 | $274,241.90 |
DisclosureSEC source: 0001093557-24-000064 · edgardoc.xml · nonDerivative · entry 1 Dolan Matthew Vincent · CIK 0001914994 · EVP Strategy and Corporate Dev 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,377 F1 · shares: On December 15, 2023, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:55 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,003 | $131.39 | $131,785.37 |
DisclosureSEC source: 0001093557-24-000056 · edgardoc.xml · nonDerivative · entry 3 Dolan Matthew Vincent · CIK 0001914994 · EVP Strategy & Corp Dev 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,367 F1 · shares: On December 15, 2023, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $131.20 to $131.70. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:55 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,314 | $130.77 | $171,832.31 |
DisclosureSEC source: 0001093557-24-000056 · edgardoc.xml · nonDerivative · entry 2 Dolan Matthew Vincent · CIK 0001914994 · EVP Strategy & Corp Dev 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,370 F1 · shares: On December 15, 2023, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $130.165 to $130.95. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:55 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,886 | $129.18 | $243,641.40 |
DisclosureSEC source: 0001093557-24-000056 · edgardoc.xml · nonDerivative · entry 1 Dolan Matthew Vincent · CIK 0001914994 · EVP Strategy & Corp Dev 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,684 F1 · shares: On December 15, 2023, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $128.78 to $129.645. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:39 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,710 | $134.41 | $901,895.80 |
DisclosureSEC source: 0001093557-24-000049 · edgardoc.xml · nonDerivative · entry 1 Dolan Matthew Vincent · CIK 0001914994 · EVP Strategy and Corporate 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,570 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 22:30 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 21,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-24-000035 · edgardoc.xml · nonDerivative · entry 1 Dolan Matthew Vincent · CIK 0001914994 · EVP Strategy and Corporate 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,280 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| September 01, 2023 Filed Sep 1, 2023 22:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 56 | $102.32 | $5,729.92 |
DisclosureSEC source: 0001093557-23-000197 · edgardoc.xml · nonDerivative · entry 1 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Strategy-Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,569 F1 · shares: On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan which was amended on December 6, 2022. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. he shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 33,569 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 20:14 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,303 | $115.00 | $264,845.00 |
DisclosureSEC source: 0001093557-23-000089 · edgardoc.xml · nonDerivative · entry 1 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Strategy-Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,569 F1 · shares: On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan which was amended on December 6, 2022. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 33,569 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,229 | $106.27 | $661,955.83 |
DisclosureSEC source: 0001093557-23-000077 · edgardoc.xml · nonDerivative · entry 5 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Strategy-Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,872 F3 · shares: On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan which was amended on December 6, 2022. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 33,569 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 787 | $111.40 | $87,671.01 |
DisclosureSEC source: 0001093557-23-000077 · edgardoc.xml · nonDerivative · entry 4 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Strategy-Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,101 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 33,569 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 2,397 | $111.40 | $267,023.40 |
DisclosureSEC source: 0001093557-23-000077 · edgardoc.xml · nonDerivative · entry 3 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Strategy-Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,888 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 33,569 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 1,650 | $111.40 | $183,808.35 |
DisclosureSEC source: 0001093557-23-000077 · edgardoc.xml · nonDerivative · entry 2 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Strategy-Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,285 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 33,569 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 1,370 | $111.40 | $152,616.63 |
DisclosureSEC source: 0001093557-23-000077 · edgardoc.xml · nonDerivative · entry 1 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Strategy-Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,935 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 33,569 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 21:00 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 21,769 | $0.00 | $21.77 |
DisclosureSEC source: 0001093557-23-000057 · edgardoc.xml · nonDerivative · entry 1 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Strategy-Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,305 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 33,569 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 01:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 226 | $114.40 | $25,854.40 |
DisclosureSEC source: 0001093557-23-000033 · edgardoc.xml · nonDerivative · entry 1 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Strategy-Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,536 F1 · shares: On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan which was amended on December 6, 2022. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 26,536 unvested restricted stock units, 11,556 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,192 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 6,788 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 13:33 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5 | $81.63 | $408.15 |
DisclosureSEC source: 0001093557-22-000155 · edgardoc.xml · nonDerivative · entry 1 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Strategy-Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,536 F1 · shares: On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Adjusted to reflect Dexcom's 4-for-1 stock split, effective on June 10, 2022. Included in this number are 26,536 unvested restricted stock units, 11,556 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,192 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 6,788 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 17, 2022 Filed Mar 17, 2022 20:30 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 484 | $450.00 | $217,800.00 |
DisclosureSEC source: 0001093557-22-000065 · edgardoc.xml · nonDerivative · entry 3 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,634 F1 · shares: On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 6,634 unvested restricted stock units, 2,889 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,048 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 16, 2022 Filed Mar 17, 2022 20:30 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 686 | $425.00 | $291,550.00 |
DisclosureSEC source: 0001093557-22-000065 · edgardoc.xml · nonDerivative · entry 2 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,118 F1 · shares: On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 6,634 unvested restricted stock units, 2,889 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,048 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:30 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,016 | $412.41 | $419,008.56 |
DisclosureSEC source: 0001093557-22-000065 · edgardoc.xml · nonDerivative · entry 1 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,804 F1 · shares: On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 6,634 unvested restricted stock units, 2,889 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,048 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:24 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 541 | $406.06 | $219,676.67 |
DisclosureSEC source: 0001093557-22-000047 · edgardoc.xml · nonDerivative · entry 5 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,820 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 6,634 unvested restricted stock units, 2,889 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,048 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:24 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 489 | $406.06 | $198,561.73 |
DisclosureSEC source: 0001093557-22-000047 · edgardoc.xml · nonDerivative · entry 4 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,361 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 6,634 unvested restricted stock units, 2,889 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,048 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:24 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 192 | $406.06 | $77,962.89 |
DisclosureSEC source: 0001093557-22-000047 · edgardoc.xml · nonDerivative · entry 3 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,850 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 6,634 unvested restricted stock units, 2,889 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,048 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:24 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 393 | $406.06 | $159,580.28 |
DisclosureSEC source: 0001093557-22-000047 · edgardoc.xml · nonDerivative · entry 2 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,042 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 6,634 unvested restricted stock units, 2,889 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,048 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 08, 2022 Filed Mar 11, 2022 00:24 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 2,889 | $0.00 | $2.89 |
DisclosureSEC source: 0001093557-22-000047 · edgardoc.xml · nonDerivative · entry 1 Dolan Matthew Vincent · CIK 0001914994 · SVP Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,435 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 6,634 unvested restricted stock units, 2,889 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,048 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.